Related Experiment Videos
Dilevalol compared with propranolol and placebo for systemic hypertension
J A Schoenberger1, W H Frishman, J D Wallin
1Rush Medical College, Chicago, IL 60612.
The American Journal of Cardiology
|June 5, 1989
Summary
Dilevalol effectively lowers blood pressure when administered once daily, matching the efficacy of twice-daily dosing and outperforming placebo. This new antihypertensive agent offers a favorable side-effect profile compared to propranolol.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Clinical Trials
Background:
- Dilevalol is a novel antihypertensive agent with dual beta 2-agonist vasodilator and nonselective beta-antagonist properties.
- Hypertension management requires effective and well-tolerated therapeutic options.
Purpose of the Study:
- To evaluate the efficacy and tolerability of once-daily dilevalol in managing mild to moderate hypertension.
- To compare once-daily dilevalol with twice-daily dilevalol, twice-daily propranolol, and placebo.
Main Methods:
- Two multicenter, double-blind studies were conducted with a placebo run-in period.
- Patients' doses were titrated over 9 weeks to achieve target blood pressure goals.
- Patients were then maintained on fixed doses for 1-2 months.
Main Results:
- Once-daily dilevalol demonstrated comparable efficacy to dilevalol and propranolol given every 12 hours in reducing supine diastolic blood pressure.
- Dilevalol was significantly superior to placebo in lowering blood pressure (p < 0.001).
- Dilevalol showed a favorable side-effect profile, with less fatigue, bradycardia, and mental depression than propranolol, but more diarrhea.
Conclusions:
- Once-daily dilevalol is an effective and well-tolerated antihypertensive treatment.
- Dilevalol offers an improved side-effect profile compared to propranolol, making it a potentially valuable option for hypertension management.